Please wait a minute...
Journal of ZheJiang University(Medical Science)  2016, Vol. 45 Issue (4): 356-363    DOI: 10.3785/j.issn.1008-9292.2016.07.05
    
Effect of a novel EZH2 inhibitor GSK126 on prostate cancer cells
LIN Weiren1, CHEN Yatian2, ZENG Linghui2, YING Rongbiao1, ZHU Feng2
1. Department of Internal Medicine, Taizhou Cancer Hospital, Wenling 317502, China;
2. School of Medicine, Zhejiang University City College, Hangzhou 310015, China
Download:   PDF(1293KB)
Export: BibTeX | EndNote (RIS)      

Abstract  

Objective: To investigate the effect of a novel EZH2 inhibitor GSK126 on cell growth, apoptosis and migration of prostate cancer cells. Methods: Prostate cancer PC-3 and DU145 cells were treated with GSK126 at different doses. Cell growth was detected by sulforhodamine assay. Cell apoptosis was assayed by Annexin V-/PI kit. Transwell chamber and wound healing assays were conducted to detect cell migration. The mRNA level was detected by quantitative PCR, and protein expression was detected by Western blot analysis. Results: GSK126 showed significant effect on cell growth and apoptosis when the dose was higher than 50 μmol/L. Wound healing assay revealed that scratch space in PC-3 cells was significantly increased in a dose-dependent manner in GSK126-treated groups[(247.2±24.4),(347.2±19.2) and (410.5±18.1) μm in low, medium and high dose (5.0, 20.0, 50.0 μmol/L), respectively] as compared with the control group[(171.3±17.8) μm](all P<0.05). Transwell assay showed that migrated PC-3 cells in control group was 322.0±17.9,while those in GSK126-treated groups were 198.3±15.4 (low),82.7±6.2 (medium) and 30.2±4.1 (high), and the differences between the control group and GSK126-treated groups were significant(all P<0.05). In addition, GSK126 up-regulated E-cadherin mRNA expression and down-regulated N-cadherin and Vimentin mRNA expression, whereas had no significant effect on Snail, Fibronectin and VEGF-A mRNA expression. The protein expression of E-cadherin was elevated but VEGF-A protein did not change in GSK126-treated groups. Similar results were exhibited in DU145 cell. Conclusion: GSK126 can significantly inhibit cell migration and invasion in prostate cancer PC-3 and DU145 cells, which may be resulted from its effect on epithelial-mesenchymal transition. GSK126 may be used as a potential anti-prostate cancer dug in clinic.



Key wordsGenes, tumor suppressor/drug effects      Prostatic neoplasms/drug therapy      Neoplasm proteins/biosynthesis      Protein methyltransferases      Cell movement      Cell proliferation      Apoptosis      Cell line, tumor     
Received: 18 February 2016     
CLC:  R73-3  
  R737.25  
Cite this article:

LIN Weiren, CHEN Yatian, ZENG Linghui, YING Rongbiao, ZHU Feng. Effect of a novel EZH2 inhibitor GSK126 on prostate cancer cells. Journal of ZheJiang University(Medical Science), 2016, 45(4): 356-363.

URL:

http://www.zjujournals.com/xueshu/med/10.3785/j.issn.1008-9292.2016.07.05     OR     http://www.zjujournals.com/xueshu/med/Y2016/V45/I4/356


zeste基因增强子同源物2抑制剂GSK126对前列腺癌细胞的作用及机制

目的:探究zeste基因增强子同源物2(EZH2)抑制剂GSK126对前列腺癌细胞增殖、凋亡及迁移的作用及机制。方法:以磺酰罗丹明B实验考察GSK126对PC-3和DU145细胞增殖的影响,以Annexin V/PI双染法考察GSK126对细胞凋亡的影响,以Transwell实验和细胞划痕实验观察GSK126对细胞迁移和侵袭的影响,以荧光定量PCR检测GSK126对肿瘤相关基因mRNA表达的影响,以蛋白质印迹法检测相关蛋白水平的变化。结果:GSK126仅在50.0 μmol/L的高浓度剂量时能有效抑制PC-3和DU145细胞增殖,并促进其凋亡。经GSK126小、中、大剂量(5.0、20.0、50.0 μmol/L)处理后,PC-3细胞划痕间距分别为(247.2±24.4)μm、(347.2±19.2)μm、(410.5±18.1)μm,与对照组(171.3±17.8)μm比较差异均有统计学意义(均P<0.05),且呈一定的量效关系。Transwell实验结果显示,每视野下侵袭的PC-3细胞数对照组为322.0±17.9,而经GSK126小、中、大剂量处理后分别为198.3±15.4、82.7±6.2、30.2±4.1,与对照组比较差异均有统计学意义(均P<0.05)。GSK126处理前列腺癌细胞后,与上皮细胞间质转化相关的E-cadherin基因mRNA表达量上升,N-cadherin、Vimentin基因mRNA表达量下降,但Snail、Fibronectin、VEGF-A基因的mRNA表达无变化。同时,蛋白质印迹法检测结果提示,E-cadherin的蛋白表达量增加,而VEGF-A蛋白表达量无明显改变。DU145细胞上述实验结果相似。结论:GSK126能有效抑制PC-3细胞和DU145细胞迁移和侵袭,其机制与抑制上皮细胞间质转化相关。GSK126可作为潜在的前列腺癌临床治疗用药。


关键词: 基因,肿瘤抑制/药物作用,  前列腺肿瘤/药物疗法,  肿瘤蛋白质类/生物合成,  蛋白甲基转移酶类,  细胞运动,  细胞增殖,  细胞凋亡,  细胞系,肿瘤 
[[1]]   LUNGLMAYR G. Efficacy and tolerability of Casodex in patients with advanced prostate cancer. International Casodex Study Group[J]. Anticancer Drugs, 1995,6(4): 508-513.
[[2]]   SHI Y, LAN F, MATSON C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1[J]. Cell, 2004, 119(7): 941-953.
[[3]]   CHEN Y, YANG Y, WANG F, et al. Crystal structure of human histone lysine-specific demethylase 1(LSD1)[J]. Proc Natl Acad Sci U S A, 2006, 103(38): 13956-13961.
[[4]]   YOU J S, JONES P A. Cancer genetics and epigenetics: two sides of the same coin?[J]. Cancer Cell, 2012, 22(1): 9-20.
[[5]]   SHEN L, CUI J, LIANG S, et al. Update of research on the role of EZH2 in cancer progression[J]. Onco Targets Ther, 2013, 6(2): 321-324.
[[6]]   REN G, BARITAKI S, MARATHE H, et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer[J]. Cancer Res, 2012,72(12): 3091-3104.
[[7]]   MCCABE M T, OTT H M, GANJI G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations[J]. Nature, 2012, 492(7427): 108-112.
[[8]]   SATO T, KANEDA A, TSUJI S, et al. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer[J]. Sci Rep, 2013, 3(5): 1911.
[[9]]   WU C, JIN X, YANG J, et al. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer[J]. Oncotarget, 2016, 7(3):3440-3452.
[[10]]   CHEN H, TU S W, HSIEH J T. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer[J]. J Biol Chem, 2005, 280(23): 22437-22444.
[[11]]   CHEN Y T, ZHU F, LIN W R, et al. The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis in via down regulating VEGF-A[J]. Cancer Chemother Pharmacol, 2016, 77(4):757-765.
[[12]]   YU J M, SUN W, HUA F, et al. BCL6 induces EMT by promoting the ZEB1-mediated transcription repression of E-cadherin in breast cancer cells[J]. Cancer Lett, 2015, 365(2): 190-200.
[[13]]   YU J, CAO Q, YU J, et al. The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer[J]. Oncogene, 2010, 29(39): 5370-5380.
[[14]]   Mcgarvey K M, Greene E, Fahrner J A, et al. DNA methylation and complete transcriptional silencing of cancer genes persist after depletion of EZH2[J]. Cancer Res, 2007, 67(11): 5097-5102.
[[15]]   陆虹昊, 马俐君. 上皮间质细胞转化的分子机制及其在肿瘤转移中的作用[J]. 中国肿瘤生物治疗杂志, 2009, 16(5): 541-545. LU Honghao, MA Lijun. The mechanism of epithelial-mesenchymal transition and its effect in tumor metastasis[J]. Chinese Journal of Cancer Biotherapy,2009, 16(5): 541-545. (in Chinese)
[1] CAO Peng, LENG Dongjin, LI Ying, ZHANG Ziwei, LIU Lei, LI Xiaoyan. Progress on anti-tumor molecular mechanisms of dihydroartemisinin[J]. Journal of ZheJiang University(Medical Science), 2016, 45(5): 501-507.
[2] LOU Pengrong, SUN Xiaonan, ZHOU Jundong, ZOU Shitao. Effect of RAD18-siRNA on proliferation and chemotherapy sensitivity of human esophageal squamous cell carcinoma ECA-109 cells[J]. Journal of ZheJiang University(Medical Science), 2016, 45(4): 364-370.
[3] CHEN Xiaojing, XU Junfen, YE Jing, CHENG Xiaodong, XIE Xing, LYU Weiguo. Expression of miR-let-7e-3p in cervical intraepithelial neoplasm and cervix carcinoma and its clinical significance[J]. Journal of ZheJiang University(Medical Science), 2016, 45(4): 342-348.
[4] WANG Cheng, WANG Wenjun, YANG Wei, YU Xiaohua, YAN Yiguo, ZHANG Jian, JIANG Zhisheng. MicroRNAs: a type of novel regulative factor for intervertebral disc degeneration[J]. Journal of ZheJiang University(Medical Science), 2016, 45(2): 170-178.
[5] XU Li, ZHU Yuan-run, CHEN Jian, YANG Xiao-chun, LUO Pei-hua. Anticancer effect of SN-38 combined with sorafenib on hepatocellular carcinoma in vitro and its mechanism[J]. Journal of ZheJiang University(Medical Science), 2015, 44(5): 486-492.
[6] YANG Min-li, YE Zhao-ming. Extremely low frequency electromagnetic field induces apoptosis of osteosarcoma cells via oxidative stress[J]. Journal of ZheJiang University(Medical Science), 2015, 44(3): 323-328.
[7] XIN Liao-bing, JIANG Xiu-xiu, YE Xiao-lei, WU Rui-jin, XU Kai-hong, MA Jun-yan, LIN Jun. AQP5 gene silencing inhibits proliferation and migration of ectopic endometrial glandular epithelial cells in endometriosis[J]. Journal of ZheJiang University(Medical Science), 2015, 44(3): 285-292.
[8] WANG Xiao-jun, ZHANG Hao, ZHAN Hong-sheng, DING Dao-fang. Establishment of chondrocyte degeneration model in vitro by rat serum[J]. Journal of ZheJiang University(Medical Science), 2015, 44(3): 308-314.
[9] HAN Yan-xia, YOU Liang-shun, LIU Hui, MAO Li-ping, YE Xiu-jin, QIAN Wen-bin. Apoptosis of acute myeloid leukemia HL-60 cells induced by CDK inhibitor SNS-032 and its molecular mechanisms[J]. Journal of ZheJiang University(Medical Science), 2015, 44(2): 174-178.
[10] TONG Xu-hui, GU Yu-chen, JIAO Hao, YU Li, DONG Shu-ying. Inhibition of gap junctional intercellular communication protects astrocytes from hypoxia/reoxygenation injury[J]. Journal of ZheJiang University(Medical Science), 2015, 44(1): 67-73.
[11] WANG Hao, GENG Zhao-ming, HU Zhi-wei, WANG Shu-yan, ZHAO Bing. Neuroprotective effects of paeonol in a cell model of Parkinson disease[J]. Journal of ZheJiang University(Medical Science), 2015, 44(1): 30-36.
[12] ZHU Hai-peng, YUN Feng, JIU Tao, et al. Inhibitory effect of inositol hexaphosphate on proliferation of LNCaP cells and its  relation to IGFBP-3 expression[J]. Journal of ZheJiang University(Medical Science), 2014, 43(5): 521-.
[13] ZHENG Yong-xia, ZHANG Cheng-wen, HUI Bin, et al. Roles of PIK3R1 gene in development of hepatocellular carcinoma[J]. Journal of ZheJiang University(Medical Science), 2014, 43(5): 559-.
[14] PAN Hui,et al. Effects of placental growth factor on revascularization after acute myocardial infarction in rats[J]. Journal of ZheJiang University(Medical Science), 2014, 43(4): 441-447.
[15] HAN Xiao-yu,ZHANG Lu,LIU Zhi-xian,HUANG Jing,ZHANG Meng,FANG San-hua,ZHANG Wei-ping,WEI Er-qing,LU Yun-bi . Effects of leukotriene D4 on proliferation and migration of lung epithelial A549 cells in vitro[J]. Journal of ZheJiang University(Medical Science), 2014, 43(3): 287-292.